Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Appendix 1: Acceptable intakes established for N-nitrosamines

Timetable: Safety referral (Article 107i, urgent Union procedure)

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

Timetable: Non-safety referrals

Human medicines European public assessment report (EPAR): Tegsedi, inotersen, Date of authorisation: 06/07/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Nugalviq, govorestat, Status: Application withdrawn

Orphan designation: daratumumab Treatment of plasma-cell myeloma, 17/07/2013 Expired

Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Date of authorisation: 13/03/2001, Revision: 51, Status: Authorised